Add this topic to your myFT Digest for news straight to your inbox
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
US tax overhaul spurs near-$30bn spree but some warn of bubble amid high valuations
French drugmaker says it will continue to reshape group as it offsets Lantus decline
Witty aims to show turnround plan is on track with strong growth in new drugs
US regulators have grown concerned over quality control and unreliable data from Indian companies
US biotech says it wants name to evoke ‘life-saving’ medicines
Microsoft, Amazon and Alphabet all rally at least 7 per cent
At least five western drugmakers have paid penalties over China corruption allegations since 2012
The pharmaceuticals industry is in a bullish mood over immunotherapies
Sir Andrew Witty has withdrawn from anti-cancer therapies to grow non-drugs side
Busiest M&A start since 2007, US cable sector deals, Quindell omits sale details, and CCB cuts pay
International Edition